Day One

Wednesday April 21

7:45 am Registration & ‘Coffee Room’ Networking

8:20 am Chair’s Opening Remarks

• Steve Sandor VP, Market Access and Trade, PARATEK PHARMACEUTICALS

8:30 am Keynote Presentation: A Review of the Antibacterial Development Pipeline

• Peter Beyer Senior Advisor and Team Lead, World Health Organization - WHO

Re-imagining Anti-Infective Drug Development to Ensure Economic Sustainability

9:00 am AMR Action Fund: Strengthening & Accelerating Antibiotic Development

• Silas Holland Head of External Affairs (Interim) & Director of Global Public Policy, The AMR Action Fund & Merck

9:25 am Surviving FDA Approval of your Antibiotic

• Kevin Outterson Executive Director & Professor of Law, CARB-X & Boston University

9:50 am Trends in the Development & Approval of New Anti-infectives: Cycle Times, Success Rates & Expedited Regulatory Pathways

• Joseph DiMasi Director of Economic Analysis, Tufts CSDD

10:15 am Q&A/Discussion

• Silas Holland Head of External Affairs (Interim) & Director of Global Public Policy, The AMR Action Fund & Merck
• Kevin Outterson Executive Director & Professor of Law, CARB-X & Boston University
• Joseph DiMasi Director of Economic Analysis, Tufts CSDD
• Steve Sandor VP, Market Access and Trade, PARATEK PHARMACEUTICALS

10:40 am Virtual Speed Networking

11:10 am Morning Break

11:40 am Expedited Regulatory Pathways for Development & Licensure of Novel Anti-Infectives

• Ercem Atillasoy Chief Regulatory & Safety Officer, AlloVir

12:05 pm Differentiated Approach to Harnessing Novel Biologics & Overcome AMR

• Jonathan Steckbeck Founder, President & Chief Executive Officer, Peptilogics

12:30 pm Q&A/Discussion

• Ercem Atillasoy Chief Regulatory & Safety Officer, AlloVir
• Jonathan Steckbeck Founder, President & Chief Executive Officer, Peptilogics
• Steve Sandor VP, Market Access and Trade, PARATEK PHARMACEUTICALS

12:50 pm Lunch & Networking Break

Exploring Non-Traditional Approaches to Combat Multi-Drug Resistance

1:50 pm Clinical Experience with crPhage in Urinary Tract Infections

• Dave Ousterout Chief Scientific Officer, Locus Biosciences

2:15 pm Human Monoclonal Antibodies for Emerging Infections

• James Crowe Director, Vanderbilt Vaccine Center

2:40 pm Fighting Fire with Fire: Live Biotherapeutics for Pulmonary Infections

• Jeanette Mucha Chief Executive Officer & Co- Founder, SciBac

3:05 pm Q&A/Discussion

• Dave Ousterout Chief Scientific Officer, Locus Biosciences
• Jeanette Mucha Chief Executive Officer & Co- Founder, SciBac
• James Crowe Director, Vanderbilt Vaccine Center

3:30 pm Afternoon Break

4:00 pm Pseudomonas Elastase (LasB) as a Therapeutic Target

• Martin Everett Chief Scientific Officer, AntaBio

4:25 pm Live Bacterial Consortia, a Novel Microbiome- Based Approach for Infection Prevention

• Silvia Caballero Associate Director of Infectious Diseases, Vedanta Biosciences

4:50 pm Q&A/Discussion

• Martin Everett Chief Scientific Officer, AntaBio
• Silvia Caballero Associate Director of Infectious Diseases, Vedanta Biosciences

5:10 pm Close of Conference Day One